Corporate Update: Quoin Pharmaceuticals Ltd. (QNRX)
Trading Performance
On Wednesday, 21 September 2026, Quoin Lt (ticker QNRX) closed 1.51 % higher after a 24‑hour trading window that concluded at 02:10 PM Central Europe. The share price, which can currently be acquired for approximately USD 4.04 on major exchanges, sits well below its simple moving average of the last 200 days, which is USD 6.39. Within the past 24 hours, the market has witnessed a trading volume of roughly USD 32.7 k, reflecting modest liquidity compared to the company’s USD 19.1 m market capitalisation.
The last month has been markedly challenging for QNRX; the stock has fallen 41.45 % since the end of August. Nonetheless, the firm’s latest clinical developments provide a narrative of potential upside, which may influence future valuation multiples.
Clinical Milestones and Regulatory Strategy
Peer‑Reviewed Publication
Quoin Pharmaceuticals has published a peer‑reviewed case report detailing the use of its investigational topical lotion, QRX003, in a single pediatric patient with Netherton syndrome. After 21 months of compassionate use, the patient experienced significant improvement in skin condition and itch, with no adverse events reported. The paper positions QRX003 as a promising candidate for further clinical evaluation.
Interim Phase 2/3 Results
In August, the company released interim data from its Phase 2/3 trial, CL‑QRX003‑004. Two of the first six participants achieved the primary efficacy endpoint after 12 weeks of treatment. Quoin aims to complete recruitment by the end of 2026 and intends to release topline data in the second quarter of 2027. The company has cautioned that these observations are preliminary and that ongoing safety and efficacy assessments are essential.
Market Context and Peer Comparisons
| Company | Recent 24‑hr Move | Current Price | Market Cap | P/E |
|---|---|---|---|---|
| Mind Cti (MNDO) | Flat (0 %) | USD 0.91 | USD 18.5 m | 5.73 |
| Cellcom Israel (CEL.TA) | Up 2.8 % | ILA 3,501 | ILA 1.9 bn | 10.07 |
| RocketDNA (RKT.AX) | Down 2.04 % | AUD 0.02 | AUD 32.8 m | — |
| Hilan (HLAN.TA) | Up 3.3 % | ILA 24,950 | ILA 1.8 bn | 21.09 |
| Nutritional Growth (NGS.AX) | Flat (0 %) | AUD 0.02 | AUD 19.3 m | — |
Quoin’s performance is comparatively subdued against peers such as Cellcom Israel and Hilan, which have posted double‑digit gains. However, RocketDNA’s recent share price decline is mirrored in QNRX’s modest rise, underscoring the sector‑wide volatility that typifies specialty pharmaceutical stocks.
Strategic Moves in the Pipeline
While Quoin remains focused on its rare‑disease portfolio, its recent clinical data suggest a trajectory that could revitalize investor sentiment. The company’s strategy includes:
- Expanding clinical evidence: Completing the Phase 2/3 trial and publishing topline results in 2027.
- Enhancing shareholder value: Communicating the therapeutic potential of QRX003 with transparent risk disclosures.
- Maintaining liquidity: Managing a supply of 4.8 million shares against a market cap that keeps the stock reasonably affordable.
Outlook
Quoin Pharmaceuticals Ltd. continues to navigate the complexities of drug development for orphan indications. The company’s current share price, trading well below its 200‑day moving average, suggests that the market is still discounting future earnings potential. Should the upcoming topline data substantiate the early promise of QRX003, we may anticipate a reevaluation of valuation multiples and a corresponding adjustment in the stock’s price trajectory.
For further information, investors may visit the company’s website at www.quoinpharma.com .
